CHGA and neuroblastoma: In a 3-year-old child (208) with a malignant neuroblastoma with elevated levels of plasma GRP and pancreastatin, there was a 30–60% decrease in the high levels with treatment with octreotide, leading the authors to suggest that assessment of plasma GRP and other peptides might be useful markers of response to treatment.